brewer
New member
- Joined
- Aug 16, 2026
- Messages
- 34
- Gender
- male
- Basic Beliefs
- atheist
Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to share information and notify clinicians, public health authorities, and the public about the risk of severe arboviral neuroinvasive disease among patients who are receiving B cell-depleting or B cell-modulating medications, particularly anti-CD20 monoclonal antibodies (mAbs). Patients and their providers should be aware of this risk to help patients protect themselves against the bites of mosquitoes and ticks, which can increase patients' risk of arboviral disease.
...
In recent years, a novel clinical presentation of chronic, neurodegenerative encephalitis developing over months to years has been described in at least five patients receiving rituximab who were infected with an orthobunyavirus, including Jamestown Canyon virus, Cache Valley virus, or Potosi virus. All patients died; diagnoses were delayed because of unrecognized infection and rare or unexpected pathogens requiring specialized diagnostic testing.
www.cdc.gov
Anti-CD20 monoclonal antibodies — which include rituximab and its biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and ibritumomab tiuxetan. Anti-CD20s, used to treat non-Hodgkin lymphoma, several leukemias, rheumatoid arthritis, pemphigus vulgaris, some types of vasculitis, multiple sclerosis (MS), and prevention of transplant rejection.
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to share information and notify clinicians, public health authorities, and the public about the risk of severe arboviral neuroinvasive disease among patients who are receiving B cell-depleting or B cell-modulating medications, particularly anti-CD20 monoclonal antibodies (mAbs). Patients and their providers should be aware of this risk to help patients protect themselves against the bites of mosquitoes and ticks, which can increase patients' risk of arboviral disease.
...
In recent years, a novel clinical presentation of chronic, neurodegenerative encephalitis developing over months to years has been described in at least five patients receiving rituximab who were infected with an orthobunyavirus, including Jamestown Canyon virus, Cache Valley virus, or Potosi virus. All patients died; diagnoses were delayed because of unrecognized infection and rare or unexpected pathogens requiring specialized diagnostic testing.
Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications
Risk of Severe Arboviral Disease in Patients Receiving B Cell-Depleting or Modulating Medications
www.cdc.gov
Anti-CD20 monoclonal antibodies — which include rituximab and its biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and ibritumomab tiuxetan. Anti-CD20s, used to treat non-Hodgkin lymphoma, several leukemias, rheumatoid arthritis, pemphigus vulgaris, some types of vasculitis, multiple sclerosis (MS), and prevention of transplant rejection.
Just when I thought I heard it all.